The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the third quarter and nine months ended 31 October 2017 on 6 December 2017.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Glyn Edwards / Richard Pye (UK office)
44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)
+1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser)
+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker)
+44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
Pamure Gordon (Joint Broker)
+44 (0)20 7886 2500
Freddy Crossley, Corporate Finance
Tom Salvesen, Corporate Broking
MacDougall Biomedical Communications (US)
+1 781 235 3060
Consilium Strategic Communications (UK)
+44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson /
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, firstname.lastname@example.org, and we will post.